Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain
Ionis, AstraZeneca Pivotal Heart Disease Drug Flunks
AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.
AstraZeneca-Ionis drug fails to meet main goal in late-stage heart disease trial
Ionis Climbs As FDA Clears New Therapy To Lower Triglycerides, Pancreatitis Risk